MY186267A - Kinase inhibitor polymorphs - Google Patents

Kinase inhibitor polymorphs

Info

Publication number
MY186267A
MY186267A MYPI2014000363A MYPI2014000363A MY186267A MY 186267 A MY186267 A MY 186267A MY PI2014000363 A MYPI2014000363 A MY PI2014000363A MY PI2014000363 A MYPI2014000363 A MY PI2014000363A MY 186267 A MY186267 A MY 186267A
Authority
MY
Malaysia
Prior art keywords
kinase inhibitor
polymorphs
activity
chemical compounds
inhibitor polymorphs
Prior art date
Application number
MYPI2014000363A
Other languages
English (en)
Inventor
Pingda Ren
Michael Martin
Original Assignee
Intellikine Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47669006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY186267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intellikine Llc filed Critical Intellikine Llc
Publication of MY186267A publication Critical patent/MY186267A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MYPI2014000363A 2011-08-11 2012-08-10 Kinase inhibitor polymorphs MY186267A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161522624P 2011-08-11 2011-08-11
PCT/US2012/050453 WO2013023184A1 (en) 2011-08-11 2012-08-10 Kinase inhibitor polymorphs

Publications (1)

Publication Number Publication Date
MY186267A true MY186267A (en) 2021-07-01

Family

ID=47669006

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2014000363A MY186267A (en) 2011-08-11 2012-08-10 Kinase inhibitor polymorphs

Country Status (25)

Country Link
US (1) US20150065524A1 (enExample)
EP (1) EP2741749A4 (enExample)
JP (1) JP2014521726A (enExample)
KR (1) KR20140079368A (enExample)
CN (1) CN103957918A (enExample)
AU (1) AU2012294202B2 (enExample)
BR (1) BR112014003214A2 (enExample)
CA (1) CA2844742A1 (enExample)
CL (1) CL2014000343A1 (enExample)
CO (1) CO6960542A2 (enExample)
CR (1) CR20140082A (enExample)
DO (1) DOP2014000027A (enExample)
EA (1) EA027970B1 (enExample)
EC (1) ECSP14013236A (enExample)
HK (1) HK1199203A1 (enExample)
IL (1) IL230850A0 (enExample)
MX (1) MX2014001662A (enExample)
MY (1) MY186267A (enExample)
PE (1) PE20141358A1 (enExample)
PH (1) PH12014500331A1 (enExample)
RU (1) RU2636588C2 (enExample)
SG (2) SG2014009492A (enExample)
TN (1) TN2014000063A1 (enExample)
WO (1) WO2013023184A1 (enExample)
ZA (1) ZA201401211B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
EP2346896A4 (en) 2008-10-15 2014-06-25 Angiochem Inc ETOPOSID AND DOXORUBICIN CONJUGATES FOR ACTIVITY EXTRACTION
US8921314B2 (en) 2008-10-15 2014-12-30 Angiochem, Inc. Conjugates of GLP-1 agonists and uses thereof
JP5759379B2 (ja) 2008-12-05 2015-08-05 アンジオケム インコーポレーテッド ニューロテンシンまたはニューロテンシンアナログおよびその使用
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
CN102596993A (zh) 2009-07-02 2012-07-18 安吉奥开米公司 多聚体肽结合物以及其应用
CN106924741A (zh) * 2011-11-08 2017-07-07 因特利凯有限责任公司 使用多种药剂的治疗方案
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途
WO2015073644A1 (en) 2013-11-13 2015-05-21 Novartis Ag Mtor inhibitors for enhancing the immune response
US10640569B2 (en) 2013-12-19 2020-05-05 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
KR102487608B1 (ko) 2014-04-07 2023-01-12 노파르티스 아게 항-cd19 키메라 항원 수용체를 사용한 암의 치료
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CN107109419B (zh) 2014-07-21 2020-12-22 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
EP3180359A1 (en) 2014-08-14 2017-06-21 Novartis AG Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
KR102804360B1 (ko) 2014-09-17 2025-05-12 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
ES2636646B1 (es) * 2016-04-05 2018-08-03 Universidade De Santiago De Compostela NUEVOS VEHÍCULOS PARA LA TRANSFECCIÓN DE miRNAs
CN116769050A (zh) 2016-07-20 2023-09-19 犹他大学研究基金会 Cd229 car t细胞及其使用方法
MX2019003886A (es) 2016-10-07 2019-08-05 Novartis Ag Receptores de antigenos quimericos para el tratamiento del cancer.
ES2837396T3 (es) 2016-11-23 2021-06-30 Bayer Cropscience Ag Derivados de 2-[3-(alquilsulfonil)-2H-indazol-2-il]-3H-imidazo[4,5-b]piridina y compuestos similares como pesticidas
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
BR112020013794B1 (pt) * 2018-01-09 2023-05-02 Halcyon Labs Private Limited Processo para a preparação de crisaborola de fórmula (i), compostos, uso de um composto de fórmula (iv), (iii) ou (ii), processo para a preparação de crisaborola altamente pura e sal
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US8476282B2 (en) * 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
AR084824A1 (es) * 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas

Also Published As

Publication number Publication date
KR20140079368A (ko) 2014-06-26
CL2014000343A1 (es) 2014-10-17
PE20141358A1 (es) 2014-10-12
CO6960542A2 (es) 2014-05-30
EA201490446A1 (ru) 2014-05-30
IL230850A0 (en) 2014-03-31
RU2636588C2 (ru) 2017-11-24
TN2014000063A1 (en) 2015-07-01
PH12014500331A1 (en) 2014-03-31
AU2012294202B2 (en) 2017-02-23
SG2014009492A (en) 2014-09-26
CR20140082A (es) 2014-06-03
EP2741749A4 (en) 2015-04-15
AU2012294202A1 (en) 2014-03-06
EP2741749A1 (en) 2014-06-18
EA027970B1 (ru) 2017-09-29
NZ622208A (en) 2016-04-29
CA2844742A1 (en) 2013-02-14
ECSP14013236A (es) 2014-06-30
WO2013023184A1 (en) 2013-02-14
DOP2014000027A (es) 2014-07-15
US20150065524A1 (en) 2015-03-05
MX2014001662A (es) 2014-08-26
JP2014521726A (ja) 2014-08-28
HK1199203A1 (en) 2015-06-26
SG10201606288TA (en) 2016-09-29
ZA201401211B (en) 2015-12-23
RU2014109023A (ru) 2015-09-20
CN103957918A (zh) 2014-07-30
BR112014003214A2 (pt) 2017-03-14

Similar Documents

Publication Publication Date Title
TN2014000063A1 (en) Kinase inhibitor polymorphs
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PH12020550450A1 (en) Certain chemical entities, compositions and methods
EP2571357A4 (en) CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINAS MODULATION
TN2012000071A1 (en) Heterocyclic compounds and uses thereof
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
PH12017502141A1 (en) Compounds and their methods of use
WO2012116237A3 (en) Heterocyclic compounds and uses thereof
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
PH12012502128B1 (en) Chemical compounds
MX2014013752A (es) Inhibidores de nampt.
SG190819A1 (en) Nampt and rock inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
PH12014502513A1 (en) Nampt inhibitors
IN2015DN00827A (enExample)
MX2014004766A (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
MX348311B (es) Inhibidores nampt.
MX2013002851A (es) Inhibidores de tonum pectinacetilesterasa y metodos de su uso.
MX370253B (es) Composiciones de compuestos de jasmonato y métodos de uso de las mismas.
MX2014013758A (es) Derivados de tiazolcarboxamida para usarse como inhibidores de nampt.
MX2013005825A (es) Benzoxazepinas como inhibidores de objetivo de rapamicina en mamiferos (mtor) y metodos de uso y fabricacion.
MX351961B (es) Analogos de diazonamida.
MX2014002343A (es) Inhibidores de parp.